Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
Tourette's Syndrome is a neurological disease characterized by motor and vocal tics. It has
been hypothesized that abnormal interactions of dopamine with its receptors may cause the
tics. The purpose of this study is to test the hypothesis that a drug (ecopipam) that
selectively blocks dopamine D1/D5 receptors can reduce the frequency and severity of the
tics.